Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Emerging Leaders
not ranked
Current Leaders
#9729 pts
All-Time Leaders
#10120 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 1998. 7 trials as lead/chair. How it works →
Trials led — by scientific impact
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab
Phase 2RecruitingNational Cancer Institute (NCI)
18
impact
A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer
Phase 2RecruitingNational Cancer Institute (NCI)
15
impact
An Assessment of the Safety and Feasibility of Administering T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With B-Cell Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)
6
impact
Phase I/II Study of Metastatic Cancer That Expresses MAGE-A3/12 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
Phase 2TerminatedNational Cancer Institute (NCI)
5
impact
A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
Phase 2TerminatedNational Cancer Institute (NCI)
4
impact
Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets
N/ACompletedNational Cancer Institute (NCI)
4
impact
A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII
Phase 2CompletedNational Cancer Institute (NCI)
4
impact
A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers
Phase 2CompletedNational Cancer Institute (NCI)
4
impact
Evaluation for NCI Surgery Branch Clinical Research Protocols
N/ARecruitingNational Cancer Institute (NCI)
4
impact
A Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor-Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI)
Phase 2CompletedNational Cancer Institute (NCI)
4
impact
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes
Phase 2TerminatedNational Cancer Institute (NCI)
4
impact
Cell Harvest and Preparation for Surgery Branch Treatment Protocols
N/AEnrolling by InvitationNational Cancer Institute (NCI)
4
impact
A Phase II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients With Metastatic Cancer
Phase 2WithdrawnNational Cancer Institute (NCI)
4
impact
Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential Future Therapy
N/ATerminatedNational Cancer Institute (NCI)
4
impact
A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
Phase 2TerminatedNational Cancer Institute (NCI)
4
impact
Phase I/II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Tumor Infiltrating Lymphocytes Genetically Engineered to Express IL-12
Phase 2TerminatedNational Institutes of Health Clinical Center (CC)
3
impact
A Pilot Trial of the Combination of Vemurafenib With Adoptive Cell Therapy in Patients With Metastatic Melanoma
Phase 1TerminatedNational Cancer Institute (NCI)
3
impact
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes
Phase 2CompletedNational Cancer Institute (NCI)
3
impact
A Phase I-II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3 HLA-A*01 Restricted TCR-Gene Engineered Lymphocytes and Aldesleukin
Phase 2TerminatedNational Cancer Institute (NCI)
3
impact
A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma
Phase 2TerminatedNational Cancer Institute (NCI)
3
impact
Phase II Study of Lymphocytes Generated With Engineered Cells for Costimulation Enhancement in Patients With Metastatic Melanoma Following Lymphodepletion
Phase 2TerminatedNational Cancer Institute (NCI)
3
impact
A Phase I/II Study of IL-15 Administration Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen and Autologous Lymphocyte Transfer in Metastatic Melanoma
Phase 2TerminatedNational Cancer Institute (NCI)
3
impact
Phase I/II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Gene Engineered Lymphocytes Cotransduced With Genes Encoding IL-12 and Anti-NY ESO-1 TCR
Phase 1TerminatedNational Cancer Institute (NCI)
3
impact
A Phase I/II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and Aldesleukin
Phase 2CompletedNational Cancer Institute (NCI)
2
impact
A Phase I Trial for the Evaluation of the In Vivo Persistence of Adoptively-transferred Tumor-Infiltrating Lymphocytes Cultured With a Pharmacologic Inhibitor of AKT in Patients With Metastatic Melanoma
Phase 1WithdrawnNational Cancer Institute (NCI)
2
impact
Phase II Study of CD62L+-Derived T Lymphocytes Transduced With a T Cell Receptor Recognizing the NY-ESO-1 Antigen and Aldesleukin Following Lymphodepletion in Patients With NY-ESO-1 Expressing Melanoma
Phase 2TerminatedNational Cancer Institute (NCI)
2
impact
A Phase II Study of Cell Transfer Therapy for Metastatic Melanoma Using 41BB Selected Tumor Infiltrating Lymphocytes Plus IL-2 Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen
Phase 2TerminatedNational Cancer Institute (NCI)
2
impact
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes
Phase 2TerminatedNational Cancer Institute (NCI)
2
impact
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes
Phase 2TerminatedNational Cancer Institute (NCI)
1
impact
Phase II Study of DNA Encoding the gp100 Antigen Alone or in Combination With Interleukin-2 in Patients With Recurrent Metastatic Melanoma
Phase 2CompletedNational Cancer Institute (NCI)Study Chair
0
impact
A Phase Ib Clinical Trial to Evaluate the Administration of Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Phase 1ActiveNational Cancer Institute (NCI)
0
impact
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
N/AEnrolling by InvitationNational Cancer Institute (NCI)
0
impact
Single Patient Protocol: A Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
Phase 2WithdrawnNational Cancer Institute (NCI)
0
impact
Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
N/AEnrolling by InvitationNational Cancer Institute (NCI)
0
impact